X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.980
+0.180 (4.74%)
At close: Dec 5, 2025, 4:00 PM EST
3.970
-0.010 (-0.25%)
After-hours: Dec 5, 2025, 6:37 PM EST
X4 Pharmaceuticals Stock Forecast
XFOR's stock price has decreased by -65.32% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for X4 Pharmaceuticals stock ranges from a low of $5.00 to a high of $90. The average analyst price target of $28.5 forecasts a 616.08% increase in the stock price over the next year.
Price Target: $28.50 (+616.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $7.5 → $10 | Strong Buy | Maintains | $7.5 → $10 | +151.26% | Dec 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.5 → $5 | Strong Buy | Maintains | $3.5 → $5 | +25.63% | Nov 10, 2025 |
| Stifel | Stifel | Strong Buy Maintains $30 → $9 | Strong Buy | Maintains | $30 → $9 | +126.13% | Aug 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $3.5 | Strong Buy | Maintains | $7 → $3.5 | -12.06% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1.5 → $7 | Strong Buy | Maintains | $1.5 → $7 | +75.88% | May 2, 2025 |
Financial Forecast
Revenue This Year
35.20M
from 2.56M
Increased by 1,276.65%
Revenue Next Year
13.78M
from 35.20M
Decreased by -60.85%
EPS This Year
-3.26
from -5.59
EPS Next Year
-1.11
from -3.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 36.8M | 23.8M | ||||
| Avg | 35.2M | 13.8M | ||||
| Low | 33.4M | 6.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,339.9% | -32.3% | ||||
| Avg | 1,276.7% | -60.8% | ||||
| Low | 1,206.9% | -82.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.01 | -0.79 | ||||
| Avg | -3.26 | -1.11 | ||||
| Low | -5.64 | -1.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.